October 28, 2005 – Bristol-Myers Squibb took a double hit today after missing its Q3 earnings/revenues forecasts and stopping development of Pargluva, its new diabetes drug; Pfizer said the FDA will take an additional 3 months before ruling on Exubera, the inhaled form of insulin; GlaxoSmithKline won FDA approval of a treatment for leukemia; Chiron received a $62.5 million US contract to provide an asian flu vaccine; Centocor and Lilly have permanently ended their Phase III test of a druf for stroke; Schering-Plough stopped a Phase II trial of a drug candidate for HIV/AIDS patients; Eisai reported the FDA did not accept its application of an add-on indication for an Alzheimer’s drug; Accentia Biopharmaceuticals made its IPO debut today; and NxStage Medical began trading yesterday. The Centient Biotech 200™ was 39 points higher at 3708.75, a gain of 1.06%. More details...
